| XLS |
|
|
|
|
|
|
€ million |
Note |
2013 |
2012 |
|
Sales |
[22] |
10,700.1 |
10,740.8 |
|
Royalty, license and commission income |
[23] |
395.0 |
432.1 |
|
Total revenues |
|
11,095.1 |
11,172.9 |
|
|
|
|
|
|
Cost of sales |
[24] |
–2,992.5 |
–3,157.7 |
|
Gross margin |
|
8,102.6 |
8,015.2 |
|
|
|
|
|
|
Marketing and selling expenses |
[25] |
–2,326.5 |
–2,410.8 |
|
Royalty, license and commission expenses |
[26] |
–567.0 |
–579.8 |
|
Administration expenses |
[27] |
–562.4 |
–552.2 |
|
Other operating expenses and income |
[28] |
–718.1 |
–1,125.9 |
|
Research and development costs |
[29] |
–1,504.3 |
–1,511.3 |
|
Amortization of intangible assets |
[30] |
–813.5 |
–871.6 |
|
Operating result |
|
1,610.8 |
963.6 |
|
|
|
|
|
|
Financial result |
[31] |
–222.2 |
–254.6 |
|
Profit before income tax |
|
1,388.6 |
709.0 |
|
|
|
|
|
|
Income tax |
[32] |
–179.5 |
–130.0 |
|
Profit after tax |
|
1,209.1 |
579.0 |
|
|
|
|
|
|
of which attributable to Merck KGaA shareholders (net income) |
|
1,202.2 |
566.7 |
|
of which attributable to non-controlling interests |
[33] |
6.9 |
12.3 |
|
|
|
|
|
|
Earnings per share (in €) |
[34] |
|
|
|
basic |
|
5.53 |
2.61 |
|
diluted |
|
5.53 |
2.61 |